Technical Analysis for CERC - Cerecor Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
2.97 | -12.13% | -0.41 |
CERC closed down 12.13 percent on Thursday, February 27, 2020, on 1.24 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 16
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical CERC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -12.13% | |
| Below Lower BB | Weakness | -12.13% | |
| Down 3 Days in a Row | Weakness | -12.13% | |
| Lower Bollinger Band Touch | Weakness | -12.13% | |
| Oversold Stochastic | Weakness | -12.13% | |
| New Downtrend | Bearish | -13.54% | |
| Stochastic Reached Oversold | Weakness | -13.54% | |
| Below Lower BB | Weakness | -13.54% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/16/2020
- Sector: Healthcare
- Industry: Biotechnology
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Chemistry Biopharmaceutical Disorders Organic Chemistry Major Depressive Disorder Depression Pyrrolidines Antidepressants Piperidines Nmda Receptor Antagonists
Chemistry Biopharmaceutical Disorders Organic Chemistry Major Depressive Disorder Depression Pyrrolidines Antidepressants Piperidines Nmda Receptor Antagonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.87 |
| 52 Week Low | 2.91 |
| Average Volume | 101,154 |
| 200-Day Moving Average | 4.09 |
| 50-Day Moving Average | 4.43 |
| 20-Day Moving Average | 3.90 |
| 10-Day Moving Average | 3.73 |
| Average True Range | 0.31 |
| ADX | 30.31 |
| +DI | 10.28 |
| -DI | 39.21 |
| Chandelier Exit (Long, 3 ATRs ) | 3.67 |
| Chandelier Exit (Short, 3 ATRs ) | 3.88 |
| Upper Bollinger Band | 4.54 |
| Lower Bollinger Band | 3.26 |
| Percent B (%b) | -0.23 |
| BandWidth | 32.83 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.19 |
| MACD Histogram | -0.0834 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.60 | ||||
| Resistance 3 (R3) | 3.67 | 3.53 | 3.50 | ||
| Resistance 2 (R2) | 3.53 | 3.37 | 3.49 | 3.46 | |
| Resistance 1 (R1) | 3.25 | 3.27 | 3.18 | 3.18 | 3.43 |
| Pivot Point | 3.10 | 3.10 | 3.07 | 3.07 | 3.10 |
| Support 1 (S1) | 2.83 | 2.94 | 2.75 | 2.76 | 2.51 |
| Support 2 (S2) | 2.68 | 2.84 | 2.65 | 2.48 | |
| Support 3 (S3) | 2.40 | 2.68 | 2.44 | ||
| Support 4 (S4) | 2.34 |
